Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.

Meeting the Demand for Lipid Excipients

Container and equipment innovations expand applications.

Innovations Meet Growing Demand for Prefilled Syringes

Genetic vaccine platforms demonstrate their potential.

Innovating to Fight the Pandemic

Materials availability is a factor in vaccine production.

Supply Chain Hurdles for Vaccine Production

Topic

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Articles

Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.

Subunit Vaccines and the Fight Against COVID-19

RECOVERY trial results have shown that Regeneron’s investigational antibody combination therapy reduces the mortality risk for seronegative hospitalized patients with severe COVID-19.

Regeneron’s Antibody Combination Therapy Reduces COVID-19 Mortality Risk

CureVac’s first-generation COVID-19 vaccine candidate, CvnCoV, did not meet efficacy targets in a second interim analysis. 

CureVac Releases Interim Results from COVID-19 Vaccine Candidate Trial

The US government will invest $3 billion from the American Rescue Plan into a COVID-19 antiviral development strategy.

Biden Administration Invests in Antiviral Medicines

Recent analysis has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.

PHE Analysis Demonstrates Efficacy of COVID Vaccines Against Delta Variant

What can the biopharma industry learn from its rapid response to the COVID-19 pandemic?

Process Development Improvements Post-Pandemic

Novavax’s COVID-19 vaccine is 90.4% effective and maintains efficacy when administered with an influenza vaccine.

Novavax Reports on Two Vaccine Efficacy Studies

The agency approved two batches of drug substance manufactured at the Emergent BioSolutions facility in Baltimore for use in the Janssen COVID-19 vaccine.

FDA Authorizes Use of Drug Substance for Janssen COVID-19 Vaccine

The new site in Monts, France, which is operated by Recipharm, will produce finished COVID-19 vaccine product.

EMA Approves New Manufacturing Site for Moderna COVID-19 Vaccine

As a safety measure, supervisory authorities in the European Union have recommended not releasing batches of Janssen’s COVID-19 vaccine with API manufactured at Emergent BioSolutions’ Maryland facility.

COVID-19 Update

Meeting the Demand for Lipid Excipients

Innovations Meet Growing Demand for Prefilled Syringes

Innovating to Fight the Pandemic

Supply Chain Hurdles for Vaccine Production